Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE: eNOS-enhanced EPCs for PAH
NCT03001414Phase 3Terminated
- Sponsor
- Northern Therapeutics
- Start
- Sep 2017
- Primary completion
- May 2023
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of autologous mononuclear cells expressing human nitric oxide synthase in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Northern Therapeutics. Primary endpoint: Change in 6 Minute Walk Distance at 6 months. Started Sep 2017; status: terminated.
02
Drugs
autologous mononuclear cells expressing human nitric oxide synthase
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03001414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03001414.